Skip to main content

Table 3 Most common adverse events during TB treatment and treatment outcomes among HIV-infected TB patients, stratified by markers for viral hepatitis infections.

From: Viral hepatitis and HIV-associated tuberculosis: Risk factors and TB treatment outcomes in Thailand

Adverse events and treatment outcomes All patients (n = 769) Non-reactive for HBsAg and anti-HCV (n = 472) Reactive for Unknown (n = 17)
    Only HBsAg (n = 43) Only anti-HCV (n = 210) HBsAg and anti-HCV (n = 27)  
  n (%) n (%) n (%) n (%) n (%) n (%)
Adverse events       
Rash 116 (15) 69 (15) 7 (16) 32 (15) 4 (15) 4 (24)
Immune reconstitution inflammatory syndrome* 16 (7) 12 (7) 0 (0) 2 (6) 1 (13) 1 (100)
Liver disease 41 (5) 23 (5) 3 (7) 12 (6) 2 (7) 1 (6)
Diarrhea 36 (5) 22 (5) 2 (5) 7 (3) 2 (7) 3 (18)
Pneumonia including PCP 30 (4) 15 (3) 2 (5) 11 (5) 1 (4) 1 (6)
Meningitis 20 (3) 11 (2) 2 (5) 6 (3) 1 (4) 0 (0)
HIV wasting syndrome 19 (3) 15 (3) 0 (0) 1 (1) 1 (4) 2 (12)
Cryptococcosis 16 (2) 8 (2) 0 (0) 8 (4) 0 (0) 0 (0)
Herpes zoster 12 (2) 5 (1) 2 (5) 4 (2) 1 (4) 0 (0)
Recurrent upper respiratory infections or sinusitis 7 (1) 5 (1) 0 (0) 0 (0) 2 (7) 0 (0)
Treatment outcomes       
Cure 210 (27) 133 (28) 7 (16) 63 (30) 6 (22) 1 (6)
Complete 283 (37) 190 (40) 16 (37) 65 (31) 9 (33) 3 (18)
Failure 6 (1) 3 (1) 1 (2) 2 (1) 0 (0) 0 (0)
Die 130 (17) 72 (15) 5 (12) 37 (18) 7 (26) 9 (53)
Default 65 (9) 34 (7) 8 (19) 20 (10) 1 (4) 2 (12)
Transfer out 70 (9) 37 (8) 5 (12) 22 (11) 4 (15) 2 (12)
On treatment 5 (1) 3 (1) 1 (2) 1 (1) 0 (0) 0 (0)
  1. TB, tuberculosis; HIV, human immunodeficiency virus; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; PCP, pneumocystis carinii pneumonia.
  2. *Among 237 patients eligible to be evaluated only.